203 related articles for article (PubMed ID: 21446702)
1. Crystal structure of tert-butyldimethylsilyl-spiroaminooxathioledioxide-thymine (TSAO-T) in complex with HIV-1 reverse transcriptase (RT) redefines the elastic limits of the non-nucleoside inhibitor-binding pocket.
Das K; Bauman JD; Rim AS; Dharia C; Clark AD; Camarasa MJ; Balzarini J; Arnold E
J Med Chem; 2011 Apr; 54(8):2727-37. PubMed ID: 21446702
[TBL] [Abstract][Full Text] [Related]
2. Identification of a putative binding site for [2',5'-bis-O-(tert-butyldimethylsilyl)-beta-D-ribofuranosyl]-3'-spiro-5''-(4''-amino-1'',2''-oxathiole-2'',2''-dioxide)thymine (TSAO) derivatives at the p51-p66 interface of HIV-1 reverse transcriptase.
Rodríguez-Barrios F; Pérez C; Lobatón E; Velázquez S; Chamorro C; San-Félix A; Pérez-Pérez MJ; Camarasa MJ; Pelemans H; Balzarini J; Gago F
J Med Chem; 2001 Jun; 44(12):1853-65. PubMed ID: 11384232
[TBL] [Abstract][Full Text] [Related]
3. Resistance of HIV-1 reverse transcriptase against [2',5'-bis-O-(tert-butyldimethylsilyl)-3'-spiro-5''-(4''-amino-1'',2''- oxathiole-2'',2''-dioxide)] (TSAO) derivatives is determined by the mutation Glu138-->Lys on the p51 subunit.
Jonckheere H; Taymans JM; Balzarini J; Velázquez S; Camarasa MJ; Desmyter J; De Clercq E; Anné J
J Biol Chem; 1994 Oct; 269(41):25255-8. PubMed ID: 7523383
[TBL] [Abstract][Full Text] [Related]
4. Human immunodeficiency virus type 1 reverse transcriptase dimer destabilization by 1-[Spiro[4"-amino-2",2" -dioxo-1",2" -oxathiole-5",3'-[2', 5'-bis-O-(tert-butyldimethylsilyl)-beta-D-ribofuranosyl]]]-3-ethylthy mine.
Sluis-Cremer N; Dmitrienko GI; Balzarini J; Camarasa MJ; Parniak MA
Biochemistry; 2000 Feb; 39(6):1427-33. PubMed ID: 10684624
[TBL] [Abstract][Full Text] [Related]
5. Differences in the inhibition of human immunodeficiency virus type 1 reverse transcriptase DNA polymerase activity by analogs of nevirapine and [2',5'-bis-O-(tert-butyldimethylsilyl)-3'-spiro-5"-(4"-amino-1", 2"-oxathiole-2",2"-dioxide] (TSAO).
Arion D; Fletcher RS; Borkow G; Camarasa MJ; Balzarini J; Dmitrienko GI; Parniak MA
Mol Pharmacol; 1996 Nov; 50(5):1057-64. PubMed ID: 8913335
[TBL] [Abstract][Full Text] [Related]
6. Abasic analogues of TSAO-T as the first sugar derivatives that specifically inhibit HIV-1 reverse transcriptase.
Velázquez S; Chamorro C; Pérez-Pérez MJ; Alvarez R; Jimeno ML; Martín-Domenech A; Pérez C; Gago F; De Clercq E; Balzarini J; San-Félix A; Camarasa MJ
J Med Chem; 1998 Nov; 41(23):4636-47. PubMed ID: 9804703
[TBL] [Abstract][Full Text] [Related]
7. TSAO derivatives, inhibitors of HIV-1 reverse transcriptase dimerization: recent progress.
Camarasa MJ; Velázquez S; San-Félix A; Pérez-Pérez MJ; Bonache MC; De Castro S
Curr Pharm Des; 2006; 12(15):1895-907. PubMed ID: 16724955
[TBL] [Abstract][Full Text] [Related]
8. 4"-H-TSAO-T, a novel prototype in the HIV-1 specific TSAO family.
Lobatón E; Velázquez S; San-Félix A; De Clercq E; Balzarini J; Camarasa MJ
Nucleosides Nucleotides Nucleic Acids; 2001; 20(4-7):711-4. PubMed ID: 11563098
[TBL] [Abstract][Full Text] [Related]
9. Unusual lability of 5'-O-tert-butyldimethylsilyl group on 4''-acyl TSAO derivatives.
de Castro S; Pérez-Pérez MJ; Lobatón E; De Clercq E; Balzarini J; Camarasa MJ; Velázquez S
Nucleosides Nucleotides Nucleic Acids; 2003; 22(5-8):959-61. PubMed ID: 14565321
[No Abstract] [Full Text] [Related]
10. Discovery of TSAO derivatives with an unusual HIV-1 activity/resistance profile.
de Castro S; García-Aparicio C; Van Laethem K; Gago F; Lobatón E; De Clercq E; Balzarini J; Camarasa MJ; Velázquez S
Antiviral Res; 2006 Aug; 71(1):15-23. PubMed ID: 16616962
[TBL] [Abstract][Full Text] [Related]
11. Human immunodeficiency virus type 1 (HIV-1) strains selected for resistance against the HIV-1-specific [2',5'-bis-O-(tert-butyldimethylsilyl)-3'-spiro- 5''-(4''-amino-1'',2''-oxathiole-2'',2''-dioxide)]-beta-D-pentofurano syl (TSAO) nucleoside analogues retain sensitivity to HIV-1-specific nonnucleoside inhibitors.
Balzarini J; Karlsson A; Vandamme AM; Pérez-Pérez MJ; Zhang H; Vrang L; Oberg B; Bäckbro K; Unge T; San-Félix A
Proc Natl Acad Sci U S A; 1993 Aug; 90(15):6952-6. PubMed ID: 7688467
[TBL] [Abstract][Full Text] [Related]
12. Synthesis and anti-HIV activity of [AZT]-[TSAO-T] and [AZT]-[HEPT] dimers as potential multifunctional inhibitors of HIV-1 reverse transcriptase.
Velázquez S; Alvarez R; San-Félix A; Jimeno ML; De Clercq E; Balzarini J; Camarasa MJ
J Med Chem; 1995 May; 38(10):1641-9. PubMed ID: 7538589
[TBL] [Abstract][Full Text] [Related]
13. Structure-activity relationships of [2',5'-bis-O-(tert-butyldimethylsilyl)-beta-D-ribofuranosyl]- 3'-spiro-5' '-(4' '-amino-1' ',2' '-oxathiole-2' ',2' '-dioxide)thymine derivatives as inhibitors of HIV-1 reverse transcriptase dimerization.
Sluis-Cremer N; Hamamouch N; San Félix A; Velazquez S; Balzarini J; Camarasa MJ
J Med Chem; 2006 Aug; 49(16):4834-41. PubMed ID: 16884295
[TBL] [Abstract][Full Text] [Related]
14. Computational analysis of aza analogues of [2',5'-bis-O-(tert-butyldimethylsilyl)-beta-D-ribofuranose]-3'-spiro-5"-(4"-amino-1",2"-oxathiole-2",2"-dioxide) (TSAO) as HIV-1 reverse transcriptase inhibitors: relevance of conformational properties on the inhibitory activity.
Soriano E; Marco-Contelles J; Tomassi C; Nguyen Van Nhien A; Postel D
J Chem Inf Model; 2006; 46(4):1666-77. PubMed ID: 16859298
[TBL] [Abstract][Full Text] [Related]
15. "Second generation" of TSAO compounds directed against HIV-1 TSAO-resistant strains.
Lobatón E; Velázquez S; Pérez-Pérez MJ; Jimeno ML; San-Félix A; De Clercq E; Balzarini J; Camarasa MJ
Nucleosides Nucleotides Nucleic Acids; 2001; 20(4-7):707-10. PubMed ID: 11563097
[TBL] [Abstract][Full Text] [Related]
16. Quantitative structure-activity relationship studies on some viral reverse transcriptase inhibitors acting as anti-HIV-1 agents.
Garg R; Gupta SP
J Enzyme Inhib; 1997 Jan; 11(3):171-81. PubMed ID: 9204386
[TBL] [Abstract][Full Text] [Related]
17. Novel concepts in the treatment of human immunodeficiency virus type 1 (HIV-1) infections by HIV-1-specific reverse transcriptase inhibitors.
Balzarini J
Verh K Acad Geneeskd Belg; 1995; 57(6):575-600. PubMed ID: 8686372
[TBL] [Abstract][Full Text] [Related]
18. Novel series of [ddN]-[TSAO-T] heterodimers as potential bi-functional inhibitors of HIV-1 RT. Studies in the linker and ddN region.
Velázquez S; Tuñón V; Jimeno ML; Pérez-Pérez MJ; San-Félix A; Chamorro C; Lobatón E; Esteban-Gamboa A; De Clercq E; Balzarini J; Camarasa MJ
Nucleosides Nucleotides; 1999; 18(4-5):1029-30. PubMed ID: 10432737
[TBL] [Abstract][Full Text] [Related]
19. Exploring the role of the 5'-position of TSAO-T. Synthesis and anti-HIV evaluation of novel TSAO-T derivatives.
Chamorro C; Pérez-Pérez MJ; Rodríguez-Barrios F; Gago F; De Clercq E; Balzarini J; San-Félix A; Camarasa MJ
Antiviral Res; 2001 Jun; 50(3):207-22. PubMed ID: 11397508
[TBL] [Abstract][Full Text] [Related]
20. Novel [2',5'-bis-O-(tert-butyldimethylsilyl)-beta-D-ribofuranosyl]- 3'-spiro-5''-(4''-amino-1'',2''-oxathiole-2'',2" -dioxide) derivatives with anti-HIV-1 and anti-human-cytomegalovirus activity.
de Castro S; Lobatón E; Pérez-Pérez MJ; San-Félix A; Cordeiro A; Andrei G; Snoeck R; De Clercq E; Balzarini J; Camarasa MJ; Velázquez S
J Med Chem; 2005 Feb; 48(4):1158-68. PubMed ID: 15715482
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]